Marathon Pharmaceuticals (section Deflazacort) Therapeutics acquired rights to Marathon Pharmaceuticals' drug Emflaza (deflazacort) for $140 million after criticism about their plan to sell the drug at... 11 KB (1,007 words) - 22:49, 5 May 2023 |
therapy (Elevidys). Other medications used include glucocorticoids (Deflazacort, Vamorolone); calcium channel blockers (Diltiazem); to slow skeletal... 26 KB (2,543 words) - 17:57, 28 April 2024 |
Hydrocortisone H02AB10 Cortisone H02AB11 Prednylidene H02AB12 Rimexolone H02AB13 Deflazacort H02AB14 Cloprednol H02AB15 Meprednisone H02AB17 Cortivazol H02AB18 Vamorolone... 1 KB (255 words) - 04:49, 18 December 2023 |
acquired the Bio-e platform in 2019. In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren)... 5 KB (470 words) - 06:15, 9 October 2023 |
(halobetasol) Cyclic ketals (16,17-cyclized): Amcinonide Budesonide Ciclesonide Deflazacort Desonide Fluclorolone acetonide (flucloronide) Fludroxycortide (flurandrenolone... 15 KB (1,639 words) - 23:52, 8 December 2023 |
(triamcinolone acetate cyclopentanonide) Budesonide Ciclesonide Cicortonide Deflazacort (azacort) Descinolone acetonide Desonide (hydroxyprednisolone acetonide)... 2 KB (123 words) - 19:45, 2 April 2024 |